Please Wait
Applying Filters...
menu
    • menu
    munit-sa-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Idronoxil

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Noxopharm clinical trial reveals anti-inflammatory response in COVID-19 patients
    Noxopharm clinical trial reveals anti-inflammatory response in COVID-19 patients

    25 Aug 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210825005860/fr

    BUSINESSWIRE
    25 Aug 2021
    Share Share
    Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’
    Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’

    23 Jul 2020

    // PRESS RELEASE

    https://www.scorrmarketing.com/news/noxopharm-reports-idronoxil-achieves-major-industry-goal-of-converting-cold-tumors-to-hot

    PRESS RELEASE
    23 Jul 2020
    Share Share
    BRIEF-Noxopharm Says U.S. FDA Grants IND Approval To Veyonda
    BRIEF-Noxopharm Says U.S. FDA Grants IND Approval To Veyonda

    21 Feb 2020

    // FINNEWSNETWORK

    https://www.finnewsnetwork.com.au/CompanyReports/Noxopharm/20200221/Noxopharm-announces-FDA-grants-IND-approval-to-Veyonda

    FINNEWSNETWORK
    21 Feb 2020
    Share Share